A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

